ADMA Biologics Inc Stock Forecast NASDAQ:ADMA

Price Target and Analyst Ratings

Most Recent Rating

On September 20, 2021 "Jefferies Financial Group" gave "$10.00" rating for ADMA. The price target was changed from $1.27 to 1.9%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-09-20	$10.00	Initiated by	Jefferies Financial Group	$1.25	$1.27→1.9%
2021-08-12	$7.00 - $6.00	Target Lowered by	HC Wainwright	$1.51	$1.53
2021-07-26	$7.00	Reiterated by	HC Wainwright	$1.63	$1.61+1.9%
2021-07-06	Buy	Target Lowered by	HC Wainwright	$1.51	$10.00 → $7.00
2021-04-05	Buy	Reiterated by	Jefferies Financial Group	$1.83	$10.00
2021-04-01	Outperform	Target Lowered by	Raymond James	$1.83	$7.00 → $6.00
2021-03-26	Buy	Reiterated by	Maxim Group	$1.81	$6.00
2021-03-26	Outperform	Target Lowered by	Raymond James	$1.81	$7.00 → $6.00
2021-01-04	Buy	Target Lowered by	HC Wainwright	$2.11	$12.00 → $11.00
2021-01-04	Buy	Reiterated by	HC Wainwright	$2.11
2020-10-01	Outperform	Target Raised by	Raymond James	$2.23	$7.00 → $9.00
2020-08-06	Buy	Initiated by	Oppenheimer	$2.86	$6.00
2020-08-06	Buy	Reiterated by	HC Wainwright	$2.86	$12.00
2020-07-28	Buy	Reiterated by	HC Wainwright	$2.79	$12.00
2020-05-22	Buy	Initiated by	Maxim Group	$2.84	$6.00
2020-05-22	Buy	Reiterated by	HC Wainwright	$2.84	$12.00
2020-05-07	Outperform	Target Lowered by	Oppenheimer	$2.62	$14.00 → $7.00

ADMA Stock Trend

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -24.41% during the next 3 months and, with a 90% probability hold a price between $0.84 and $1.04 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-23	$1.11	$1.24	$1.37
2021-09-24	$1.10	$1.23	$1.36
2021-09-27	$1.10	$1.22	$1.35
2021-09-28	$1.09	$1.22	$1.35
2021-09-29	$1.08	$1.21	$1.34
2021-09-30	$1.07	$1.20	$1.33
2021-10-01	$1.07	$1.20	$1.33
2021-10-04	$1.06	$1.19	$1.32
2021-10-05	$1.05	$1.18	$1.31
2021-10-06	$1.05	$1.18	$1.30
2021-10-07	$1.04	$1.17	$1.30
2021-10-08	$1.03	$1.16	$1.29
2021-10-11	$1.02	$1.15	$1.28
2021-10-12	$1.02	$1.15	$1.28
2021-10-13	$1.01	$1.14	$1.27
2021-10-14	$1.00	$1.13	$1.26
2021-10-15	$1.00	$1.13	$1.26
2021-10-18	$0.99	$1.12	$1.25
2021-10-19	$0.98	$1.11	$1.24
2021-10-20	$0.98	$1.10	$1.23
2021-10-21	$0.97	$1.10	$1.23
2021-10-22	$0.96	$1.09	$1.22
2021-10-25	$0.95	$1.08	$1.21
2021-10-26	$0.95	$1.08	$1.21
2021-10-27	$0.94	$1.07	$1.20
2021-10-28	$0.93	$1.06	$1.19
2021-10-29	$0.93	$1.06	$1.18
2021-11-01	$0.92	$1.05	$1.18
2021-11-02	$0.91	$1.04	$1.17
2021-11-03	$0.91	$1.03	$1.16

About ADMA Biologics Inc

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate is RI-002, a plasma-derived, polyclonal immune globulin intravenous that is in Phase III clinical study for the treatment of primary immune deficiency disease. The company also operatesADMA BioCenters Georgia, Inc, which is a... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!